E B Arushanian

Learn More
After chronic use of melatonin (3 mg before night-time for 14 days) campimetry showed a significant decrease of the threshold of brilliance sensitiveness of the retina in the absence of authentic changes of the sensorimotor response latency in individuals of the older age group. A connection between the eye light sensitivity and the direct effect of the(More)
Chronic administration of the pineal hormone melatonin in a low dose (0.75 mg) improved memory and optimized individual time perception in a group of young volunteers. These changes were pronounced even two weeks after termination of the drug administration. The expression of the melatonin effect was depended on the chronotype of humans tested.
Pineal hormone melatonin, which is known to possess neuroptotector and nootrope activity, also produces a significant therapeutic effect with respect to various brain pathologies. The review of original and published data suggests that it is expedient to use melatonin in the treatment of cognitive disorders accompanying Parkinson's disease.
The pineal hormone melatonin (0.1 mg/kg) produced a more pronounced antistressor effect as compared to the anxiolytic diazepam (same dose) in rats, which was manifested by decreased anxiety, improved heart rhythm variability, and prevented stress-induced violation of circadian locomotion. It is suggested that differences may result from more expressed(More)
Experimental hemorrhagic stroke causes behavior and locomotor activity with memory impairment and neurological disturbances in rats. These shifts are weaker in the evening hours than after morning testing. The repeated administration of the pineal gland hormone melatonin (melaxen) during one week significantly decreases behavior and neurological deficits as(More)